Biogen Inc. (BIIB)
Nasdaq · Healthcare · Drug Manufacturers - General
$223.59+1.69%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $33.0B
- P/E (trailing)
- 39.7
- Forward P/E
- 13.5
- 52-week range
- $138.00 – $230.49
- 52-week change
- +42.73%
- EPS (trailing)
- $5.63
- Analyst rating
- 1.9 Buy
- Next earnings
- Oct 28, 2026
Fiscal year to Dec 2025
- Revenue
- $9.9B (+2.22%)
- Net income
- $1.3B
- Diluted EPS
- $8.79
- Free cash flow
- $2.1B
From the company’s annual report on SEC EDGAR.
About Biogen Inc.
Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc.
Headquarters: Cambridge, United States · 7,500 employees · biogen.com